SS
NMRA icon

SBI Securities’s Neumora Therapeutics NMRA Stock Holding History

SBI Securities’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34 Buy
20
+2
+11% +$4 ﹤0.01% 3752
2026
Q1 		$35 Sell
18
-1
-5% -$3 ﹤0.01% 3646
2025
Q4 		$34 Buy
19
+1
+6% +$2 ﹤0.01% 3665
2025
Q3 		$33 Buy
18
+6
+50% +$10 ﹤0.01% 3809
2025
Q2 		$9 Buy
12
+9
+300% +$7 ﹤0.01% 4025
2025
Q1 		$3 Buy
+3
New +$5 ﹤0.01% 4069

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SBI Securities's NMRA Position: Q2 2026 in Review

SBI Securities increased its Neumora Therapeutics (NMRA) stake by 11% in Q2 2026, buying an estimated $4 and bringing the position to 20 shares worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #3752.

SBI Securities first reported a position in NMRA in Q1 2025 and has held it in 6 quarters since. The position peaked at $35 in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • SBI Securities held 20 shares of Neumora Therapeutics worth $34 as of Q2 2026.
  • SBI Securities bought 2 Neumora Therapeutics shares in Q2 2026, an estimated $4.
  • Neumora Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3752 holding.
  • SBI Securities first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • SBI Securities's Neumora Therapeutics position peaked at $35 in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.